Detailed price information for Marker Therapeutics Inc (MRKR-Q) from The Globe and Mail including charting and trades.

The segment spotlighted the Baylor-led research recently published in Nature Medicine evaluating autologous Multi-Antigen Targeted T cell therapy in patients with pancreatic ductal adenocarcinoma ...

Magnetic nanoparticles engineered T cells inside living mice and guided them into solid tumors, achieving over 90% tumor ...

T-cell engagers are antibody-based therapeutics that can reprogram T cells for antigen-specific elimination of target cells. The modality has remained a big draw for Big Pharma, with Eli Lilly penning ...

Cancer immunotherapy has completely changed our understanding of how cancer can and should be treated. A prime example is chimeric antigen receptor (CAR) T-cell therapy, where T cells are harvested ...

Please provide your email address to receive an email when new articles are posted on . Cell-free fetal antigen analyses had 100% consistency for 465 calls on antigens in which women were ...

EPFL researchers have successfully engineered cells of the immune system to more effectively recognize cancer cells. The work, covered in two papers, turns the previously lab-based method into a ...

Basal cell carcinoma has low immunogenicity. Tumor cells express Foxc1 protein (red), which suppresses HLA class I (green) in the tumor cells. Compromised antigen presentation ranks among the top ...

A new discovery about how cells communicate with each other in the body's immune system has revealed deeper insights for an ...